Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapyGordon Cook, A. John Ashcroft, Guy Pratt et al.|British Journal of Haematology|2020Cited by 111
Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patientsRosemary A. Barnes, Jonathan Kell, P. Lewis White et al.|Journal of Clinical Pathology|2008Cited by 91
Risk of relapse of multiple myeloma following kidney transplantationSapna Shah, Reuben Benjamin, Maria Ibrahim et al.|Clinical Kidney Journal|2018Cited by 27
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, Rakesh Popat, William Wilson et al.|The Lancet Haematology|2022Cited by 25
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee Yong, Sarah Brown, Samantha Hinsley et al.|Haematologica|2021Cited by 15